Evestia Clinical and Atlantic Research Group Join Forces to Create Global CRO Powerhouse

In a significant move that reshapes the landscape of contract research organizations (CROs), Evestia Clinical and Atlantic Research Group have announced their merger to form a global entity. The newly combined company, which will retain the Evestia Clinical name, aims to leverage the strengths of both organizations to provide enhanced expertise in key therapeutic areas and late-stage clinical trials.

Merger Details and Strategic Vision

The merger, announced on July 15, 2025, brings together two CROs from opposite sides of the Atlantic Ocean. While the financial terms of the deal remain undisclosed, the strategic rationale is clear: to create a more robust, globally-oriented organization capable of meeting the complex needs of pharmaceutical and biotech clients worldwide.

Lyle Camblos, President of Atlantic Research Group, and Paul Bishop, CEO, expressed their enthusiasm for the merger, stating, "The highly experienced and globally recognized leadership team at Evestia Clinical is building a world-class specialist CRO provider and we are excited to bring across our whole team on this journey. We are pleased that our customers will be able to benefit from this seamless continuity as well as the combined group's enhanced capabilities."

Expanded Capabilities and Geographic Reach

The newly formed Evestia Clinical will double in size as a result of the merger, significantly expanding its operational capacity and geographic footprint. The company will maintain dual headquarters, with locations in Letchworth, UK, and Charlottesville, Virginia, USA, positioning it to serve clients more effectively across multiple time zones and regulatory environments.

The combined entity will offer specialized expertise in several key therapeutic areas, including:

• Oncology
• Immunology
• Neurology
• Late-stage clinical trials

This focused approach allows Evestia Clinical to provide tailored solutions to clients working on some of the most challenging and promising areas of drug development.

Industry Consolidation Trend

The Evestia-Atlantic merger is part of a broader trend of consolidation within the CRO industry. Earlier this year, Julius Clinical and Peachtree BioResearch Solutions merged after nearly a decade of collaboration, focusing primarily on central nervous system diseases. This pattern of strategic combinations suggests that CROs are seeking to build more comprehensive service offerings and expand their global reach to better compete in an increasingly complex and internationalized drug development landscape.

As the pharmaceutical industry continues to evolve, with a growing emphasis on specialized therapies and global clinical trials, the formation of larger, more capable CROs like Evestia Clinical represents a strategic response to changing market demands. The success of this merger will likely be closely watched by industry observers as a potential model for future consolidations in the CRO space.